Sanofi loses bid to revive Lantus Solostar insulin-pen patents

In a win for Sanofi-competitor Viatris, Sanofi's attempt to keep its patent for the blockbuster insulin injection pen, Lantus SoloStar, has been rejected by the US Court of Appeals.

Photo: CHARLES PLATIAU/Reuters / X00217

Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc. 

A review board was correct to invalidate five patents for a pen-type injection device that allows a user to set and administer a dose of medication, the US Court of Appeals for the Federal Circuit said in a series of three rulings Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs